The drug transporter-metabolism alliance: Uncovering and defining the interplay

Molecular Pharmaceutics

Volumn 6, Issue 6, 2009, Pages 1631-1643

  Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atorvastatin; BDDCS; Biopharmaceutics drug disposition system; Cyclosporine; Digoxin; Erythromycin; Felodipine; Glyburide; Intestine; Liver; Metabolic enzymes; Midazolam; Rifampin; Sirolimus; Tacrolimus; Transporter enzyme interplay; Transporters

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; CYCLOSPORIN; CYCLOSPORIN A; CYSTEINE PROTEINASE INHIBITOR; CYTOCHROME P450 3A; DIGOXIN; ELACRIDAR; ERYTHROMYCIN; FELODIPINE; FUROSEMIDE; GLIBENCLAMIDE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; INTESTINE ENZYME; K77; KETOCONAZOLE; LANSOPRAZOLE; LIVER ENZYME; MIDAZOLAM; ORGANIC ANION TRANSPORTER 2; PACLITAXEL; PROTEINASE INHIBITOR; QUINIDINE; RAPAMYCIN; RIFAMPICIN; TACROLIMUS; TARIQUIDAR; TROLEANDOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; CARCINOMA CELL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG TRANSPORT; HUMAN; INTESTINE ABSORPTION; LABORATORY TEST; LIVER METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

ANIMALS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 CYP3A; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE TRANSPORT PROTEINS; MODELS, BIOLOGICAL; P-GLYCOPROTEIN; PROTEIN BINDING; RATS;

EID: 71949106600     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp900253n     Document Type: Review

References (62)

1. Wacher, V. J.; Salphati, L.; Benet, L. Z. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug Delivery Rev. 1996, 20, 99-112.
2. Benet, L. Z.; Wu, C.-Y.; Hebert, M. F.; Wacher, V. J. Intestinal drug metabolism and antitransport processes: a potential paradigm shift in oral drug delivery. J. Controlled Release 1996, 39, 139-143.
3. Gupta, S. K.; Manfro, R. C.; Tomlanovich, S. J.; Gambertoglio, J. G.; Garovoy, M. R.; Benet, L. Z. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J. Clin. Pharmacol. 1990, 30, 643-653.
4. Gupta, S. K.; Benet, L. Z. Absorption kinetics of cyclosporine in healthy volunteers. Biopharm. Drug Dispos. 1989, 10, 591-596. (Pubitemid 19272492)
5. Gupta, S. K.; Benet, L. Z. High fat meals increase the clearance of cyclosporine. Pharm. Res. 1990, 7, 46-48.
6. Hebert, M. F.; Roberts, J. P.; Prueksaritanont, T.; Benet, L. Z. Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin. Pharmacol. Ther. 1992, 52, 453-457.
7. Kolars, J. C.; Schmiedlin-Ren, P.; Scheutz, J. D.; Fang, C.; Watkins, P. B. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J. Clin. Invest. 1992, 90, 1871-1878.
8. Kolars, J. C.; Lown, K. S.; Schmiedlin-Ren, P.; Ghosh, M.; Fang, C.; Wrighton, S. A.; Merion, R. M.; Watkins, P. B. CYP3A gene expression in human gut epithelium. Pharmacogenomics 1994, 4, 247-259. (Pubitemid 24337433)
9. Gomez, D. Y.; Wacher, V. J.; Tomlanovich, S. J.; Hebert, M. F.; Benet, L. Z. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin. Pharmacol. Ther. 1995, 58, 15-19.
10. Wu, C.-Y.; Benet, L. Z.; Hebert, M. F.; Gupta, S. K.; Rowland, M.; Gomez, D. Y.; Wacher, V. J. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin. Pharmacol. Ther. 1995, 58, 492-497.
11. Wacher, V. J.; Wu, C.-Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol. Carcinog. 1995, 13, 129-134.
12. Schuetz, E. G.; Beck, W. T.; Schuetz, J. D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinatedly upregulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 1996, 49, 311-318.
13. Schuetz, E. G.; Schinkel, A. H.; Relling, M. V.; Schuetz, J. D. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 4001-4005.
14. Floren, L. C.; Bekersky, I.; Benet, L. Z.; Mekki, Q.; Dressler, D.; Lee, J. W.; Roberts, J. P.; Hebert, M. F. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole. Clin. Pharmacol. Ther. 1997, 62, 41-49. (Pubitemid 27327098)
15. Hebert, M. F.; Fisher, R. M.; Marsh, C. L.; Dressler, D.; Berkersky, I. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 1999, 39, 91-96. (Pubitemid 29053157)
16. Floren, L. C.; Christians, U.; Zimmerman, J. J.; Neefe, L.; Schorer, R.; Rushworth, D.; Harper, D.; Renz, J.; Benet, L. Z. Sirolimus oral bioavailability increases ten-fold with concomitant ketoconazole. Clin. Pharmacol. Ther. 1999, 65, 159.
17. Chang, T.; Benet, L. Z.; Hebert, M. F. Effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin. Pharmacol. Ther. 1996, 59, 297-303. (Pubitemid 26122201)
18. Dintaman, J. M.; Silverman, J. A. Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 100 succinate (TPGS). Pharm. Res. 1999, 16, 1550-1556.
19. Zhang, Y.; Benet, L. Z. The gut as a barrier to drug absorption. Clin. Pharmacokinet. 2001, 40, 159-168.
20. van Asperen, J; van Tellingen, O; Sparreboom, A.; Schinkel, A. H; Borst, P; Nooijen, W. J; Beijnen, J. H. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br. J. Cancer 1997, 76, 1181-1183.
21. Sparreboom, A.; van Asperen, J; Mayer, U.; Schinkel, A. H.; Smit, J. W.; Meijer, D. K.; Borst, P.; Nooijen, W. J.; Beijnen, J. H.; van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 2031-2035.
22. Yamaji, H.; Matsumura, Y.; Yoshikawa, y.; Takada, K. Pharmacokinetic interactions between HIV protease inhibitors in rats. Biopharm. Drug Dispos. 1999, 20, 241-247.
23. Lin, J. H.; Chiba, M.; Chen, I. W.; Nishime, J. A.; deLuna, F. A.; Yamazaki, M; Lin, Y. J. Effect of dexamethasone on the intestinal first-pass metabolism of indinavir in rats: evidence of cytochrome P-4503A and P-glycoprotein induction. Drug Metab. Dispos. 1999, 27, 1187-1193.
24. Kim, R. B.; Fromm, M. F.; Wandel, C.; Leake, B.; Wood, A. J.; Romen, D. M.; Wilkinson, G. R. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101, 289-294.
25. Zhang, Y.; Hsieh, Y.; Izumi, T.; Lin, E. T; Benet, L. Z. Effects of ketoconazole on the intestinal metabolism, transport and oral bioavailability of K02, a novel vinylsulfone peptidomimetic cysteine protease inhibitor and a P450 3A, P-glycoprotein dual substrate, in male Sprague-Dawley rats. J. Pharmacol. Exp. Ther 1998, 287, 246-252.
26. Salphati, L.; Benet, L. Z. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 1998, 56, 308-313.
27. Song, S.; Suzuki, H.; Kawai, R.; Sugiyama, Y. Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats. Drug Metab. Dispos. 1999, 27, 689-694. (Pubitemid 29252443)
28. Artursson, P.; Borchardt, R. T. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharm. Res. 1997, 14, 1655-1658. (Pubitemid 28062907)
29. Cummins, C. L.; Mangravite, L. M.; Benet, L. Z. Characterizing the expression of CYP3A4 and efflux transporters (P-gp, MRP1, and MRP2) in CYP3A4-transfected Caco-2 cells after induction with sodium butyrate and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Pharm. Res. 2001, 18, 1102-1109.
30. Cummins, C. L.; Jacobsen, W.; Benet, L. Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 2002, 300, 1036-1045.
31. Cummins, C. L.; Jacobsen, W.; Christians, U.; Benet, L. Z. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther. 2004, 308, 143-155.
32. Cummins, C. L.; Salphati, L.; Reid, M. J.; Benet, L. Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 2003, 305, 306-314.
33. Wu, C.-Y.; Benet, L. Z. Disposition of tacrolimus in isolated perfused rat liver: influence of troleandomycin, cyclosporine, and GG918. Drug Metab. Dispos. 2003, 31, 1292-1295.
34. Benet, L. Z.; Cummins, C. L.; Wu, C.-Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 2004, 277, 3-9.
35. Zhang, L.; Dresser, M. J.; Gray, A. T.; Yost, S. C.; Terashita, S.; Giacomini, K. M. Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 1997, 51, 913-921. (Pubitemid 27249124)
36. Shitara, Y.; Sugiyama, D.; Kusuhara, H.; Kato, Y.; Abe, T.; Meier, P. J.; Itoh, T.; Sugiyama, Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. Pharm. Res. 2002, 19, 147-153. (Pubitemid 34165399)
37. Hagenbuch, B.; Meier, P. J. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 2003, 1609, 1-18.
38. Sun, H.; Huang, Y.; Frassetto, L.; Benet, L. Z. Effects of uremic toxin on hepatic uptake and metabolism of erythromycin. Drug Metab. Dispos. 2004, 32, 1239-1246.
39. Lau, Y. Y.; Okochi, H.; Huang, Y.; Benet, L. Z. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems. J. Pharmacol. Exp. Ther. 2006, 316, 762-771. (Pubitemid 43131004)
40. Satoh, H.; Yamashita, F.; Tsujimoto, M.; Murakami, H.; Koyabu, N.; Ohtani, H.; Sawada, Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 2005, 33, 518-523. (Pubitemid 40393194)
41. Lam, J. L.; Benet, L. Z. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interacations: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab. Dispos. 2004, 32, 1311-1316.
42. Lau, Y. Y.; Wu, C.-Y.; Okochi, H.; Benet, L. Z. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J. Pharmacol. Exp. Ther. 2004, 308, 1040-1045.
43. Lam, J. L.; Okochi, H.; Huang, Y.; Benet, L. Z. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: characterizing the importance of transporter-enzyme interplay. Drug Metab. Dispos. 2006, 34, 1336-1344.
44. Lau, Y. Y.; Okochi, H.; Huang, Y.; Benet, L. Z. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab. Dispos. 2006, 34, 1175-1181.
45. Watkins, P. B.; Murray, S. A.; Winkelman, L. G.; Heuman, D. M.; Wrighton, S. A.; Guzelian, P. S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. J. Clin. Invest. 1989, 83, 688-697.
46. Rivory, L. P. Erythromycin breath test. Clin. Pharmacol. Ther. 2001, 70, 395-399.
47. Benet, L. Z. There are no useful CYP3A probes that quantitatively predict the in vivo kinetics of other CYP3A substrates and no expectation that one will be found. Mol. Interventions 2005, 5, 79-83.
48. Baker, A. L.; Kotake, A. N.; Schoeller, D. A. Clinical utility of breath tests for the assessment of hepatic function. Semin. Liver Dis. 1983, 3, 318-329.
49. Kurnik, D.; Wood, A. J. J.; Wilkinson, G. R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther. 2006, 80, 228-234.
50. Frassetto, L. A.; Poon, S.; Tsourounis, C.; Valera, C.; Benet, L. Z. Effects of uptake and efflux transporter inhibition on erythromycin breath test results. Clin. Pharmacol. Ther. 2007, 81, 828-832.
51. Lau, Y. Y.; Huang, Y.; Frassetto, L.; Benet, L. Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 2007, 81, 194-204. (Pubitemid 46174816)
52. Lam, J. L.; Shugarts, S. B.; Okochi, H.; Benet, L. Z. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism. J. Pharmacol. Exp. Ther. 2006, 319, 864-870.
53. Zhang, H. X.; Huang, Y.; Frassetto, L. A.; Benet, L. Z. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin. Pharmacol. Ther. 2009, 85, 78-85.
54. Wu, C.-Y.; Benet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a Biopharmaceutics Drug Disposition Classification System. Pharm. Res. 2005, 22, 11-23.
55. Food and Drug Administration, Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Food and Drug Administation, Rockville, MD, 2000. Retrieved from www.fda.gov/cder/guidance/ index.htm.
56. Watanabe, T.; Maeda, K.; Kondo, T.; Nakayama, H.; Horita, S.; Kusuhara, H.; Sugiyama, Y. Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab. Dispos. 2009, 37, 1471-1479.
57. Kusuhara, H.; Sugiyama, Y. In vitro-in vivo extrapolation of transporter-mediated clearance in the liver and kidney. Drug Metab. Pharmacokinet. 2009, 24, 37-52.
58. Watanabe, T.; Kusuhara, H.; Maeda, K.; Kanamaru, H.; Saito, Y.; Hu, Z.; Sugiyama, Y. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab. Dispos., Oct 29, 2009 [Epub ahead of print].
59. Rowland, M.; Benet, L. Z.; Graham, G. G. Clearance concepts in pharmacokinetics. J. Pharmacokinet. Biopharm. 1973, 1, 123-135.
60. Jacobsen, W.; Kuhn, B.; Soldner, A.; Kirchner, G.; Sewing, K.-F.; Kollman, P. A.; Benet, L. Z.; Christians, U. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab. Dispos. 2000, 28, 1369-1378. (Pubitemid 30797122)
61. Shugarts, S.; Benet, L. Z. The role of transporters in the pharmacokinetics of orally administered drugs. Pharm. Res. 2009, 26, 2039-2054.
62. Grover, A.; Benet, L. Z. Effects of drug transporters on volume of distribution. AAPS J. 2009, 11, 250-261.